9.1.1 ANALYTICAL CORE SHARED SERVICE The overall mission of the Analytical Core Shared Service (ACSS) is to provide Cancer Center invesfigators with centralized resources and expertise in performing analytical chemistry assays and pharmacokinefic and pharmacodynamic data analysis and interpretation. Specifically, the Analytical Core Shared Service has the following aims: ?To provide support in developing and implementing chromatography-based bioanalytical assays for quarifification of cancer therapeufic and preventive agents, nutrients, carcinogens, and endogenous biochemicals in biological specimens; ?To provide support in quanfitafive analysis of cancer therapeutic and preventive agents, nutrients, carcinogens, and endogenous biochemicals in clinical and preclinical specimens; ?To provide support in developing proper sample handling and storage conditions for specimens collected for bioanalytical assays; ?To provide support in designing pharmacokinetic sample collection schedules and pharmacokinefic and pharmacodynamic data analysis and interpretafion. These services allow for the assessment of drug/nutrient/carcinogen exposure and disposition. Services provided by ACSS also support measurement of endogenous chemicals as surrogate cancer-risk biomarkers and pharmacodynamic endpoints. These lines of research have been essential to many projects currently being carried out at the Arizona Cancer Center, especially in programs with an emphasis in drug development and cancer prevenfion research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023074-34
Application #
8377789
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
34
Fiscal Year
2012
Total Cost
$134,132
Indirect Cost
$45,596
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26
Padilla-Rodriguez, Marco; Parker, Sara S; Adams, Deanna G et al. (2018) The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun 9:2980
Hupple, Clinton W; Morscher, Stefan; Burton, Neal C et al. (2018) A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206
Smithey, Megan J; Venturi, Vanessa; Davenport, Miles P et al. (2018) Lifelong CMV infection improves immune defense in old mice by broadening the mobilized TCR repertoire against third-party infection. Proc Natl Acad Sci U S A 115:E6817-E6825
Maisel, Sabrina; Broka, Derrick; Schroeder, Joyce (2018) Intravesicular epidermal growth factor receptor subject to retrograde trafficking drives epidermal growth factor-dependent migration. Oncotarget 9:6463-6477
Daenthanasanmak, Anusara; Wu, Yongxia; Iamsawat, Supinya et al. (2018) PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. J Clin Invest 128:2787-2801
Augustus, Gaius J; Ellis, Nathan A (2018) Colorectal Cancer Disparity in African Americans: Risk Factors and Carcinogenic Mechanisms. Am J Pathol 188:291-303

Showing the most recent 10 out of 1336 publications